NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Forecast, Price & News $4.55 0.00 (0.00%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$4.46▼$4.6450-Day Range$3.76▼$4.7452-Week Range$3.30▼$6.58Volume60,252 shsAverage Volume56,394 shsMarket Capitalization$114.98 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Capricor Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside262.6% Upside$16.50 Price TargetShort InterestBearish1.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$12,180 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.41) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.77 out of 5 starsMedical Sector757th out of 983 stocksPharmaceutical Preparations Industry380th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, Capricor Therapeutics has a forecasted upside of 262.6% from its current price of $4.55.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.17% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 10.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CAPR. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,180.00 in company stock.Percentage Held by Insiders12.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.06% of the stock of Capricor Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.41) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 18.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Capricor Therapeutics (NASDAQ:CAPR) StockCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Stock News HeadlinesMay 21, 2023 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Research Coverage Started at StockNews.comMay 17, 2023 | marketwatch.comCell Therapy and Acellular Therapy Market Growth Opportunities Till 2030June 3, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 14, 2023 | americanbankingnews.comCapricor Therapeutics (NASDAQ:CAPR) Shares Pass Below 200 Day Moving Average of $4.26May 13, 2023 | finance.yahoo.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Shares Could Be 27% Above Their Intrinsic Value EstimateMay 11, 2023 | msn.comRecap: Capricor Therapeutics Q1 EarningsMay 11, 2023 | finance.yahoo.comCapricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | marketwatch.comDilated Cardiomyopathy Therapeutics Market Growth 2023-2030June 3, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 10, 2023 | americanbankingnews.comCapricor Therapeutics (CAPR) Scheduled to Post Quarterly Earnings on ThursdayMay 4, 2023 | finance.yahoo.comCapricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11April 27, 2023 | finance.yahoo.comCapricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ PlatformApril 19, 2023 | marketwatch.com2023-2030 Restrictive Cardiomyopathy Treatment Market Size with [85 Pages] includes Industry Chain Analysis | New Report by Absolute ReportsApril 19, 2023 | marketwatch.comExosome Diagnostic and Therapeutics Market Size and Market Status Forecast growing with a CAGR of 10.6% from 2023 to 2030April 14, 2023 | marketwatch.comThe Emergence of Exosome Therapy Technology Market: Implications for the Market and Consumer Behavior.April 8, 2023 | americanbankingnews.comCapricor Therapeutics Inc (NASDAQ:CAPR) Insider Xavier Avat Sells 3,000 SharesApril 5, 2023 | marketwatch.comExosome Therapy Technology Market Growth Predictions and Forecast 2030April 3, 2023 | marketwatch.comCell Therapy Market 2023 Huge Demand, Growth Opportunities and Expansion by 2029March 24, 2023 | marketwatch.comCell Therapy Market Size, Share and Forecast 2031March 23, 2023 | finance.yahoo.comCapricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 22, 2023 | americanbankingnews.comCapricor Therapeutics Inc Forecasted to Post FY2023 Earnings of ($1.41) Per Share (NASDAQ:CAPR)March 20, 2023 | finance.yahoo.comWhen Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Become Profitable?March 18, 2023 | finance.yahoo.comCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call TranscriptMarch 17, 2023 | markets.businessinsider.comMaxim Group Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)March 16, 2023 | marketwatch.comGlobal Intravenous-to-Subcutaneous Drugs Market Size Report Analysis, 2023-2029March 15, 2023 | finance.yahoo.comCapricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 14, 2023 | msn.comEarnings Preview For Capricor TherapeuticsSee More Headlines CAPR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CAPR Company Calendar Last Earnings3/15/2023Today6/03/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CAPR CUSIPN/A CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$16.50 High Stock Price Forecast$18.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+262.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,020,000.00 Net MarginsN/A Pretax Margin-523.02% Return on Equity-222.20% Return on Assets-53.66% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual Sales$2.55 million Price / Sales45.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book18.20Miscellaneous Outstanding Shares25,270,000Free Float22,111,000Market Cap$114.98 million OptionableNot Optionable Beta4.00 Key ExecutivesFrank I. Litvack M.D. (Age 59)Independent Executive Chairman of the Board Linda Marban Ph.D. (Age 51)President, Chief Executive Officer, Director Anthony Bergmann (Age 32)Chief Financial Officer, Principal Accounting Officer Karen G. Krasney J.D. (Age 62)Executive Vice President, General Counsel Thomas Lyle Copmann Ph.D. (Age 61)Vice President - Regulatory Affairs and Drug Development Houman Hemmati M.D.Ph.D., Vice President - Medical & Clinical Development, New TherapiesLuis Rodriguez-Borlado Ph.D.Vice President - Regenerative TherapiesRachel Smith Ph.D. (Age 36)Vice President - Research & Development Deborah Ascheim M.D.Chief Medical OfficerJoshua A. Kazam (Age 40)Director More ExecutivesKey CompetitorsCytomX TherapeuticsNASDAQ:CTMXViveon Health AcquisitionNYSE:VHAQReviva PharmaceuticalsNASDAQ:RVPHOncolytics BiotechNASDAQ:ONCYSeelos TherapeuticsNASDAQ:SEELView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 5,579 shares on 5/16/2023Ownership: 0.917%Susquehanna International Group LLPSold 95,600 shares on 5/16/2023Ownership: 0.000%Renaissance Technologies LLCBought 7,500 shares on 5/12/2023Ownership: 0.121%Group One Trading L.P.Sold 7,800 shares on 5/12/2023Ownership: 0.000%Charles Schwab Investment Management Inc.Bought 13,479 shares on 5/12/2023Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions CAPR Stock - Frequently Asked Questions Should I buy or sell Capricor Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CAPR shares. View CAPR analyst ratings or view top-rated stocks. What is Capricor Therapeutics' stock price forecast for 2023? 2 Wall Street research analysts have issued 12 month price targets for Capricor Therapeutics' stock. Their CAPR share price forecasts range from $15.00 to $18.00. On average, they anticipate the company's stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 262.6% from the stock's current price. View analysts price targets for CAPR or view top-rated stocks among Wall Street analysts. How have CAPR shares performed in 2023? Capricor Therapeutics' stock was trading at $3.86 at the beginning of the year. Since then, CAPR shares have increased by 17.9% and is now trading at $4.55. View the best growth stocks for 2023 here. Are investors shorting Capricor Therapeutics? Capricor Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 294,800 shares, an increase of 11.0% from the April 30th total of 265,700 shares. Based on an average daily trading volume, of 72,100 shares, the days-to-cover ratio is presently 4.1 days. View Capricor Therapeutics' Short Interest. When is Capricor Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our CAPR earnings forecast. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings data on Wednesday, March, 15th. The biotechnology company reported ($0.31) EPS for the quarter. The biotechnology company had revenue of $0.96 million for the quarter, compared to analysts' expectations of $0.01 million. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD). What is Capricor Therapeutics' stock symbol? Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR." Who are Capricor Therapeutics' major shareholders? Capricor Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.56%), Geode Capital Management LLC (0.92%), Dimensional Fund Advisors LP (0.39%), Renaissance Technologies LLC (0.12%), Commonwealth Equity Services LLC (0.12%) and Virtu Financial LLC (0.07%). Insiders that own company stock include David B Musket and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Capricor Therapeutics' stock price today? One share of CAPR stock can currently be purchased for approximately $4.55. How much money does Capricor Therapeutics make? Capricor Therapeutics (NASDAQ:CAPR) has a market capitalization of $114.98 million and generates $2.55 million in revenue each year. The biotechnology company earns $-29,020,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. How can I contact Capricor Therapeutics? Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The official website for the company is www.capricor.com. The biotechnology company can be reached via phone at 310-358-3200, via email at kimberly@argotpartners.com, or via fax at 415-875-7075. This page (NASDAQ:CAPR) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.